Webinar: Plasmid platform facilitates transition to clinic

Discover how a plasmid DNA manufacturing platform process is helpful from preclinical studies to scaling production for late-stage and commercial needs.

The demand for plasmid DNA, a critical component to many biological therapeutics, has grown concurrently with advances and successes in cell, gene and mRNA therapies. A plasmid DNA manufacturing platform can support early activities and facilitate the transition towards GMP production for clinical and commercial supply. Securing the supply of this critical raw material will help biotech and pharma companies throughout the drug development lifecycle of their advanced therapies.